Etanercept 25mg + Sulfasalazine
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate to Severe Active Axial Spondyloarthritis
Conditions
Moderate to Severe Active Axial Spondyloarthritis
Trial Timeline
Nov 1, 2005 → Jul 1, 2013
NCT ID
NCT00844142About Etanercept 25mg + Sulfasalazine
Etanercept 25mg + Sulfasalazine is a phase 2 stage product being developed by Pfizer for Moderate to Severe Active Axial Spondyloarthritis. The current trial status is unknown. This product is registered under clinical trial identifier NCT00844142. Target conditions include Moderate to Severe Active Axial Spondyloarthritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00844142 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Moderate to Severe Active Axial Spondyloarthritis